- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | Cyclerion und Medsteer kooperieren bei der Entwicklung einer neuartigen Depressionstherapie | 1 | Investing.com Deutsch | ||
| 05.01. | Cyclerion-Aktie mit massivem Kurssprung nach strategischer Kooperation mit Medsteer | 7 | Investing.com Deutsch | ||
| 05.01. | Cyclerion partners with Medsteer to advance depression treatment platform | 1 | Investing.com | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 69 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen | |
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.09.25 | Cyclerion cycles through latest pivot, reinventing itself as neuro biotech | 4 | FierceBiotech | ||
| 23.09.25 | Cyclerion sichert sich MIT-Lizenz für Programm gegen therapieresistente Depressionen | 1 | Investing.com Deutsch | ||
| 23.09.25 | Cyclerion signs MIT license for treatment-resistant depression program | 1 | Investing.com | ||
| 23.09.25 | Cyclerion stock soars after MIT licensing deal to relaunch company | 1 | Investing.com | ||
| 23.09.25 | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09.25 | Cyclerion Therapeutics, Inc.: Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | 200 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen | |
| 05.08.25 | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,63 | +0,04 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,04 | 0,00 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| QIAGEN | 46,430 | 0,00 % | AKTIE IM FOKUS: Qiagen testen Dreijahreshoch - Übernahmefantasie als Treiber | FRANKFURT (dpa-AFX) - Nach einem Sprung auf den höchsten Stand seit Februar 2023 hat die Aktie von Qiagen am Donnerstag ihre Gewinne fast vollständig abgegeben. Zuletzt ging es nur noch um 0,5 Prozent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,860 | +3,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,220 | -0,57 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,560 | +0,42 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,960 | +1,37 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| NUVALENT | 106,01 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,590 | 0,00 % | Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns | ||
| ARCELLX | 68,55 | +1,26 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ERASCA | 9,605 | -3,56 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,000 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| CG ONCOLOGY | 53,30 | -0,95 % | What Analysts Are Saying About CG Oncology Stock | ||
| KINIKSA PHARMACEUTICALS | 43,200 | +2,37 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,02 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen |
Das Unternehmen CYCLERION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,90 % bei einem Aktienkurs von 1,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.